Is venetoclax/venetoclax a targeted drug or a chemotherapy drug?

Venetoclax/Venetoclax is a targeted drug, not a chemotherapy drug. Targeted drugs refer to drugs that can selectively interfere with the growth and survival of tumor cells. They work by targeting specific molecules or signaling pathways in cancer cells, rather than directly affecting cells quickly as traditional chemotherapy drugs do.

Veneclar is a novel orally bioavailable small molecule inhibitor for selectively targeting B-cell lymphoma-2 (BCL-2), which has been shown to have high efficacy and safety in different hematological diseases, particularly in chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML). The unique properties of venetoclax, particularly its high selectivity for the BCL-2 protein and lower hematological toxicity compared with its congeners, make it a promising drug for the future treatment of B-cell malignancies. The drug has demonstrated clinical efficacy as a single agent in a number of hematologic malignancies that harbor high levels of BCL-2.

Targeted drugs have several advantages over chemotherapy drugs. First of all, targeted drugs are more targeted and can kill tumor cells more effectively while causing less harm to normal cells. Second, targeted drugs often have fewer or milder side effects and are better tolerated by patients. Finally, targeted drugs often provide longer-lasting effects and reduce relapse rates.

However, like other medications, venetoclax may still cause some adverse effects. Therefore, it is still necessary to closely follow your doctor's instructions when using this drug and to conduct regular monitoring and evaluation during treatment.